Macropore Inc. IR-Pages
MacroPore Biosurgery To Outline Corporate Growth Strategy-Conf. Call 01-15-04
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
MacroPore Biosurgery To Outline Corporate Growth Strategy
– Conference Call and Webcast to be held January 15, 2004 at 4:30 p.m. CET –
San Diego, CA, January 12, 2004 – Macropore Biosurgery, Inc. (Frankfurt: XMP)
(MacroPore) today announced it will outline its corporate strategy January 15th,
2004 at 4:30 p.m. CET (German time) or 10:30 a.m. EST. MacroPore’s CEO,
Christopher J. Calhoun, and CSO, Marc H. Hedrick will be hosting the conference
call and slide presentation.
MacroPore’s management will specifically address the company’s plan for
capitalizing on the regenerative medicine opportunity, provide an update on its
spine and orthopedics business unit, detail the cardiovascular cell therapy
program and its development milestone timelines and briefly discuss the
strategic rationale for divesting SurgiWrap. A question and answer session will
immediately follow.
To access the audio portion of the conference via telephone, please dial +49 (0)
61 03-4 85 30 01 from Germany and +1 303-262-2211 from the United States. To
reserve a line, please email Stefanie Bacher, Manager Investor Relations, at
sbacher@macropore.com. To access the conference via the internet or to access
the slide presentation, visit the investor relations section of MacroPore’s
website at http://www.macropore.com .
A telephone replay will be available for 24 hours. To access the replay please
call +49 (0) 69-5 89 99 05 68 (PIN-Number: 132271#). A slide-synchronized audio
replay of the call will be available on the homepage approximately two hours
following the call.
About MacroPore Biosurgery
MacroPore Biosurgery (Frankfurt: XMP) (MacroPore) is the global leader in the
discovery and development of regenerative medicine technologies and therapies.
We are committed to improving the practice of medicine by creating innovative
products that address two important segments of medicine: spine and orthopedic
repair and cardiovascular disease. Our surgical implants, which represent one of
the latest advancements in spine and orthopedic medicine, are manufactured at
MacroPore and marketed exclusively through Medtronic Sofamor Danek.
Additionally, we are developing a cell-based therapy to regenerate damaged heart
muscle resulting from myocardial infarction. The approach will be based on a
cell-therapy system, currently under development, capable of isolating
regenerative cells from adipose tissue. For further information please visit our
web site http://www.macropore.com .
Contact:
Tom Baker
MacroPore Biosurgery
Media and U.S. Investors
Tel. +1-858-458-0900
tbaker@macropore.com
Stefanie Bacher
MacroPore Biosurgery
European Investors
Tel. +1-858-362-0365
sbacher@macropore.com
MacroPore’s Disclaimer This press release may include forward-looking statements
regarding events and trends which may affect MacroPore Biosurgery’s future
operating results and financial position. Such statements are subject to risks
and uncertainties that could cause MacroPore Biosurgery’s actual results and
financial position to differ materially. These risks and uncertainties are
described (under the heading “Risk Factors”) in our 2002 Annual Report which is
available on our web site. MacroPore Biosurgery assumes no responsibility to
publicly release the results of any revision of forward-looking statements to
reflect events, trends or circumstances after the date they are made.
end of message, (c)DGAP 12.01.2004
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
120930 Jän 04
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found